IPN Ipsen SA

Ipsen - April 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen - April 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights

and shares composing the share capital

(in accordance with Article L.233-8 II of the French Commercial Code and

Article 223-16 of the General Regulation of the Autorité des Marchés Financiers)

Market: Euronext Paris

ISIN Code: FR 0010259150

LEI: 549300M6SGDPB4Z94P11

Date Total number of shares composing the share capital Total number of voting rights (1)
30 April 2025 83,814,526 Gross total* of voting rights: 131,926,335
Net total** of voting rights: 130,817,797

(1) Existence of a statutory clause imposing an obligation to declare threshold crossing complementary to the one relative to the legal thresholds (Article 10).

* Gross total = total number of voting rights attached to the total number of shares, including the number of shares which benefit of double voting rights and the number of treasury shares. The « Gross total » is used as a basis for the calculation of threshold crossings.

** Net total = total number of voting rights attached to the total number of shares – shares without voting rights.

Attachment



EN
12/05/2025

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. - Lancement du programme de rachat d'actions

Ipsen S.A. - Lancement du programme de rachat d'actions Information réglementée    Ipsen lance un programme de rachat d’actions pour couvrir son programme d’attribution d’actions gratuites aux salariés PARIS, FRANCE, 2 juin 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) annonce ce jour avoir confié à un prestataire de services d’investissement un mandat à l’effet de racheter un nombre maximum d’actions Ipsen S.A. de 600 000 titres, représentant environ 0,72 % du capital social, sur une période maximum de six mois. Les actions ainsi rachetées seront principalement affectées à la couverture du pla...

22h / 11m 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. - Initiation of the share buy-back program

Ipsen S.A. - Initiation of the share buy-back program Regulated information    Ipsen initiates a share buy-back program to cover its free employee share-allocation plan PARIS, FRANCE, 2 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it has appointed an investment-services provider to purchase an aggregate number of Ipsen S.A. shares up to 600,000, or about 0.72% of the share capital, over a maximum period of six months. The shares purchased under this agreement will be allocated mainly to cover Ipsen’s free employee share-allocation plan. This program is made pursuant ...

22h / 11m 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Late-breaking analysis demonstrates characteristics associated with lo...

Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma1 Post-hoc analysis of NAPOLI 3 study determined characteristics associated with long-term survival, with median overall survival of 19.5 months amongst long-term survivors receiving Onivyde® plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) regimen as a first-line therapy2 Dose reductions and/...

May 31, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Une analyse « Late Breaking » démontre les caractéristiques associées ...

Une analyse « Late Breaking » démontre les caractéristiques associées à la survie globale à long terme des patients avec un adénocarcinome pancréatique métastatique traités par Onivyde® L’essai de Phase III NAPOLI 3 est la plus grande étude interventionnelle réalisée à ce jour avec la plus longue période de suivi des patients avec un adénocarcinome pancréatique métastatique1.L’analyse post-hoc de l’étude NAPOLI 3 a permis de déterminer les caractéristiques associées à la survie à long terme, avec une survie globale médiane de 19,5 mois parmi les patients survivants à long terme recevant Oni...

May 31, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. - Annual General Meeting held on 21 May 2025

Ipsen S.A. - Annual General Meeting held on 21 May 2025     Annual General Meeting of Ipsen S.A. held on 21 May 2025 All the resolutions submitted to the shareholders’ vote have been adopted PARIS, FRANCE, 21 May 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announces today that the Annual General Meeting of the Company was held on Wednesday 21 May, 2025 at the Salons de l'Hôtel des Arts et Métiers, 9 bis, avenue d'Iéna, 75116 Paris (France), under the chairmanship of Mr. Marc de GARIDEL, Chairman of the Board of Directors, and in the presence of the members of the Board of Directors and t...

May 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch